A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...
The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...
Please provide your email address to receive an email when new articles are posted on . After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results